Page 41 - MEMOCiberer014-ENG

OTHER RD KNOWLEDGE AND INNOVATION TRANSFER ACTIVITIES
As part of the continuous activity of 2014, public-private collaboration was encouraged through work meetings with private companies or entities to present specific opportunities to collaborate with CIBERER . A number of meetings were held to explore the collaboration pathways in future projects . The companies that were contacted include: Orphan Europe, Roche, CABANA genetics, CYDAN, Valentia Biopharma, Janus Developments and Pfizer .
Furthermore one-time agreements were also maintained with different companies for R&D collaboration .
• Collaboration agreement with Sistemas Genómicos, S.L to manage samples obtained by Sistemas Genómicos, S .L . and the assignment thereof to CIBERER-BIOBANK .
• Agreement with EVERIS to participate in the collaborative AMER project in the CDTI Innterconecta call for proposals .
• Agreement with Orphan Europe for a pharmacovigilance study in the European homocystinuria registry (E-HOD) .
CREATION OF THE FIRST CIBER SPIN-OFF
One of the main milestones of 2014 has been the launch of the first Spin-off with the participation of CIBER, Epidisease S.L . This Spin-off is the result of the work and the experience of its developers, U733 of the CIBERER headed by Dr . Federico Pallardó, and carried out by Dr . Garcia Gimenez, hired by CIBERER, in the field of epigenetics .
www.ciberer.es 41